Sigilon Therapeutics, Inc. — Operating Income by Fiscal Year
3 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/08b92f45-2256-48c3-9652-539d1d30fb47/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2022 | $-43.7M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-003716 |
| FY 2021 | $-75.6M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-003555 |
| FY 2020 | $-52.6M | 2020-01-01 – 2020-12-31 | evidence 0001558370-22-003555 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Sigilon Therapeutics, Inc. — all facts · Revenue · Net Income